XML 26 R11.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Investments (Notes) | 12 Months Ended
--- | ---
Jan. 02, 2016
Investments [Abstract] |
Investments | Investments Marketable Debt Securities Investments in marketable debt securities were comprised of the following (in thousands):
| January 2, 2016
| Amortized Cost |  | Unrealized Gains |  | Unrealized Losses |  | Fair Value
Corporate bonds | $ | 7,532 |  |  | $ | — |  |  | $ | (19 | ) |  | $ | 7,513 |
Municipal bonds | 5,114 |  |  | — |  |  | (3 | ) |  | 5,111 |
U.S. Agency bonds | 2,497 |  |  | — |  |  | (1 | ) |  | 2,496 |
| $ | 15,143 |  |  | $ | — |  |  | $ | (23 | ) |  | $ | 15,120 |
| January 3, 2015
| Amortized Cost |  | Unrealized Gains |  | Unrealized Losses |  | Fair Value
U.S. Treasury securities | $ | 32,507 |  |  | $ | 12 |  |  | $ | (23 | ) |  | $ | 32,496 |
Corporate bonds | 35,409 |  |  | 2 |  |  | (36 | ) |  | 35,375 |
U.S. Agency bonds | 22,545 |  |  | 4 |  |  | (10 | ) |  | 22,539 |
Municipal bonds | 11,157 |  |  | 2 |  |  | (5 | ) |  | 11,154 |
Commercial paper | 12,487 |  |  | — |  |  | (1 | ) |  | 12,486 |
| $ | 114,105 |  |  | $ | 20 |  |  | $ | (75 | ) |  | $ | 114,050 |
Maturities of marketable debt securities were as follows (in thousands):
| January 2, 2016 |  | January 3, 2015
| Amortized Cost |  | Fair Value |  | Amortized Cost |  | Fair Value
Marketable debt securities – current (due in less than one year) | $ | 6,575 |  |  | $ | 6,567 |  |  | $ | 69,607 |  |  | $ | 69,609 |
Marketable debt securities – non-current (due in one to two years) | 8,568 |  |  | 8,553 |  |  | 44,498 |  |  | 44,441 |
| $ | 15,143 |  |  | $ | 15,120 |  |  | $ | 114,105 |  |  | $ | 114,050 |
During 2015, 2014 and 2013, respectively, we received proceeds of $127.5 million, $54.2 million and $53.3 million, respectively, from marketable debt securities. Other Investments We previously held a minority equity investment in one of our strategic product-development partners, BAM Labs, Inc. In September 2015, we completed the acquisition of the remaining outstanding capital stock of BAM Labs, Inc. The carrying value of our equity investment in BAM Labs, Inc. prior to the acquisition was $6.0 million based on the cost method. In connection with the acquisition, our equity investment was remeasured to a fair value of $12.9 million, resulting in a $3.5 million gain net of expenses, including $3.4 million of acquisition-related expenses. The remeasured fair value of our equity investment was based on the fair value of BAM Labs, Inc. at the acquisition date. The net gain of $3.5 million is included in general and administrative expenses on our consolidated statement of operations for the fiscal year ended January 2, 2016. See Note 2, Acquisition of BAM Labs, Inc., for details regarding this acquisition.

X
- Definition The entire disclosure for investment holdings. This includes the information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12) -URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010 + Details
Name: | us-gaap_InvestmentHoldingsScheduleOfInvestmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration